227 related articles for article (PubMed ID: 24581231)
21. MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition.
Burke JF; Schlosser L; Harrison AD; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2013 Nov; 20(12):3862-8. PubMed ID: 23900743
[TBL] [Abstract][Full Text] [Related]
22. Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.
Hu C; Dadon T; Chenna V; Yabuuchi S; Bannerji R; Booher R; Strack P; Azad N; Nelkin BD; Maitra A
Mol Cancer Ther; 2015 Jul; 14(7):1532-9. PubMed ID: 25931518
[TBL] [Abstract][Full Text] [Related]
23. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.
Lin YH; Chen BY; Lai WT; Wu SF; Guh JH; Cheng AL; Hsu LC
Naunyn Schmiedebergs Arch Pharmacol; 2015 Jan; 388(1):19-31. PubMed ID: 25164962
[TBL] [Abstract][Full Text] [Related]
24. Curcuminoid EF24 enhances the anti-tumour activity of Akt inhibitor MK-2206 through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer.
Chen X; Dai X; Zou P; Chen W; Rajamanickam V; Feng C; Zhuge W; Qiu C; Ye Q; Zhang X; Liang G
Br J Pharmacol; 2017 May; 174(10):1131-1146. PubMed ID: 28255993
[TBL] [Abstract][Full Text] [Related]
25. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
26. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
Ou DL; Lee BS; Lin LI; Liou JY; Liao SC; Hsu C; Cheng AL
Mol Cancer; 2014 Jan; 13():2. PubMed ID: 24387108
[TBL] [Abstract][Full Text] [Related]
27. Isobavachalcone isolated from
Li Y; Qin X; Li P; Zhang H; Lin T; Miao Z; Ma S
Drug Des Devel Ther; 2019; 13():1449-1460. PubMed ID: 31118579
[No Abstract] [Full Text] [Related]
28. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
Ramakrishnan V; Kimlinger T; Haug J; Painuly U; Wellik L; Halling T; Rajkumar SV; Kumar S
PLoS One; 2012; 7(11):e50005. PubMed ID: 23185517
[TBL] [Abstract][Full Text] [Related]
29. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab.
Iida M; Brand TM; Campbell DA; Starr MM; Luthar N; Traynor AM; Wheeler DL
Cancer Biol Ther; 2013 Jun; 14(6):481-91. PubMed ID: 23760490
[TBL] [Abstract][Full Text] [Related]
30. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
[TBL] [Abstract][Full Text] [Related]
31. The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.
Wang Q; Wei F; Lv G; Li C; Liu T; Hadjipanayis CG; Zhang G; Hao C; Bellail AC
BMC Cancer; 2013 Nov; 13():521. PubMed ID: 24182354
[TBL] [Abstract][Full Text] [Related]
32. Akt/Ezrin Tyr353/NF-κB pathway regulates EGF-induced EMT and metastasis in tongue squamous cell carcinoma.
Wang Y; Lin Z; Sun L; Fan S; Huang Z; Zhang D; Yang Z; Li J; Chen W
Br J Cancer; 2014 Feb; 110(3):695-705. PubMed ID: 24346284
[TBL] [Abstract][Full Text] [Related]
33. MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death.
Jiao P; Zhou YS; Yang JX; Zhao YL; Liu QQ; Yuan C; Wang FZ
Mol Cell Biochem; 2013 Oct; 382(1-2):217-24. PubMed ID: 23797319
[TBL] [Abstract][Full Text] [Related]
34. A novel cyano derivative of 11-keto-β-boswellic acid causes apoptotic death by disrupting PI3K/AKT/Hsp-90 cascade, mitochondrial integrity, and other cell survival signaling events in HL-60 cells.
Khan S; Kaur R; Shah BA; Malik F; Kumar A; Bhushan S; Jain SK; Taneja SC; Singh J
Mol Carcinog; 2012 Sep; 51(9):679-95. PubMed ID: 21751262
[TBL] [Abstract][Full Text] [Related]
35. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
[TBL] [Abstract][Full Text] [Related]
36. Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex.
Fang W; Che X; Li G; Wang A; Wang Y; Shi X; Hou K; Zhang X; Qu X; Liu Y
J Exp Clin Cancer Res; 2020 May; 39(1):82. PubMed ID: 32381104
[TBL] [Abstract][Full Text] [Related]
37. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206.
Cheng Y; Ren X; Zhang Y; Patel R; Sharma A; Wu H; Robertson GP; Yan L; Rubin E; Yang JM
Cancer Res; 2011 Apr; 71(7):2654-63. PubMed ID: 21307130
[TBL] [Abstract][Full Text] [Related]
38. DHA2, a synthesized derivative of bisbibenzyl, exerts antitumor activity against ovarian cancer through inhibition of XIAP and Akt/mTOR pathway.
Pang Y; Si M; Sun B; Niu L; Xu X; Lu T; Yuan H; Lou H
Food Chem Toxicol; 2014 Jul; 69():163-74. PubMed ID: 24751974
[TBL] [Abstract][Full Text] [Related]
39. Silibinin induces cell death through reactive oxygen species-dependent downregulation of notch-1/ERK/Akt signaling in human breast cancer cells.
Kim TH; Woo JS; Kim YK; Kim KH
J Pharmacol Exp Ther; 2014 May; 349(2):268-78. PubMed ID: 24472723
[TBL] [Abstract][Full Text] [Related]
40. SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF.
Saeinasab M; Bahrami AR; González J; Marchese FP; Martinez D; Mowla SJ; Matin MM; Huarte M
J Exp Clin Cancer Res; 2019 Apr; 38(1):172. PubMed ID: 31014355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]